Details of the Drug

General Information of Drug (ID: DMBZWQL)

Drug Name
Clemastine
Synonyms
Clemastina; Clemastinum; Meclastin; Meclastine; Mecloprodin; Tavegyl; Tavist; CLEMASTINE FUMARATE; HS 592; Clemastina [INN-Spanish]; Clemastine [USAN:BAN]; Clemastinum [INN-Latin]; HS-592; Tavegyl (TN); Tavist (TN); Tavist (*Fumarate*); (+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine; (+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine; (2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine; (2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine; (2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine; 2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine; 2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
Indication
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [1], [2]
Therapeutic Class
Antiallergic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 343.9
Topological Polar Surface Area (xlogp) 5
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is rapidly absorbed from the gastrointestinal tract [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Elimination
5% of drug is excreted from urine in the unchanged form [4]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.38965 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 2.3 mg/mL [4]
Chemical Identifiers
Formula
C21H26ClNO
IUPAC Name
(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
Canonical SMILES
C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
InChI
InChI=1S/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1
InChIKey
YNNUSGIPVFPVBX-NHCUHLMSSA-N
Cross-matching ID
PubChem CID
26987
ChEBI ID
CHEBI:3738
CAS Number
15686-51-8
DrugBank ID
DB00283
TTD ID
D0C5XC
VARIDT ID
DR00796
ACDINA ID
D00135

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [6], [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Allergic rhinitis
ICD Disease Classification CA08.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Clemastine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Clemastine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Triprolidine DM7SWIA Moderate Additive anticholinergic effects by the combination of Clemastine and Triprolidine. Vasomotor/allergic rhinitis [CA08] [16]
Methdilazine DMAUHQX Moderate Additive anticholinergic effects by the combination of Clemastine and Methdilazine. Vasomotor/allergic rhinitis [CA08] [16]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Clemastine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [16]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Clemastine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [17]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Clemastine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Dexbrompheniramine DMKVWGE Moderate Additive anticholinergic effects by the combination of Clemastine and Dexbrompheniramine. Vasomotor/allergic rhinitis [CA08] [16]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Clemastine and Cetirizine. Vasomotor/allergic rhinitis [CA08] [18]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Clemastine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [16]
Azatadine DMZ80SB Moderate Additive anticholinergic effects by the combination of Clemastine and Azatadine. Vasomotor/allergic rhinitis [CA08] [16]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Clemastine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Clemastine and Scopolamine. Addictive disorder [6C50-6C5Z] [16]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Clemastine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [17]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Clemastine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [17]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Clemastine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [16]
Tacrine DM51FY6 Moderate Antagonize the effect of Clemastine when combined with Tacrine. Alzheimer disease [8A20] [19]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Clemastine and Memantine. Alzheimer disease [8A20] [16]
Galantamine DMEO794 Moderate Antagonize the effect of Clemastine when combined with Galantamine. Alzheimer disease [8A20] [19]
Rivastigmine DMG629M Moderate Antagonize the effect of Clemastine when combined with Rivastigmine. Alzheimer disease [8A20] [19]
Donepezil DMIYG7Z Moderate Antagonize the effect of Clemastine when combined with Donepezil. Alzheimer disease [8A20] [19]
Hydroxyzine DMF8Y74 Moderate Additive anticholinergic effects by the combination of Clemastine and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [16]
Promazine DMZAL7W Moderate Additive anticholinergic effects by the combination of Clemastine and Promazine. Appearance/behaviour symptom [MB23] [16]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Clemastine and Desipramine. Attention deficit hyperactivity disorder [6A05] [16]
Linezolid DMGFPU2 Moderate Additive CNS depression effects by the combination of Clemastine and Linezolid. Bacterial infection [1A00-1C4Z] [20]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Clemastine and Cariprazine. Bipolar disorder [6A60] [16]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Clemastine and Loperamide. Bowel habit change [ME05] [21]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Clemastine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [22]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Clemastine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [22]
Ipratropium DMFQ320 Moderate Additive anticholinergic effects by the combination of Clemastine and Ipratropium. Chronic obstructive pulmonary disease [CA22] [22]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Clemastine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [22]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Clemastine and Olopatadine. Conjunctiva disorder [9A60] [23]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Clemastine and Ethanol. Cystitis [GC00] [23]
Trimipramine DM1SC8M Moderate Additive anticholinergic effects by the combination of Clemastine and Trimipramine. Depression [6A70-6A7Z] [16]
Cyclobenzaprine DM1YBRM Moderate Additive anticholinergic effects by the combination of Clemastine and Cyclobenzaprine. Depression [6A70-6A7Z] [16]
Imipramine DM2NUH3 Moderate Additive anticholinergic effects by the combination of Clemastine and Imipramine. Depression [6A70-6A7Z] [16]
Nortriptyline DM4KDYJ Moderate Additive anticholinergic effects by the combination of Clemastine and Nortriptyline. Depression [6A70-6A7Z] [16]
Isocarboxazid DMAF1NB Moderate Additive CNS depression effects by the combination of Clemastine and Isocarboxazid. Depression [6A70-6A7Z] [20]
Tranylcypromine DMGB5RE Moderate Additive CNS depression effects by the combination of Clemastine and Tranylcypromine. Depression [6A70-6A7Z] [20]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Clemastine and OPC-34712. Depression [6A70-6A7Z] [16]
Phenelzine DMHIDUE Moderate Additive CNS depression effects by the combination of Clemastine and Phenelzine. Depression [6A70-6A7Z] [20]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Clemastine and Clomipramine. Depression [6A70-6A7Z] [16]
Amitriptyline DMK7F9S Moderate Additive anticholinergic effects by the combination of Clemastine and Amitriptyline. Depression [6A70-6A7Z] [16]
Amoxapine DMKITQE Moderate Additive anticholinergic effects by the combination of Clemastine and Amoxapine. Depression [6A70-6A7Z] [16]
Protriptyline DMNHTZI Moderate Additive anticholinergic effects by the combination of Clemastine and Protriptyline. Depression [6A70-6A7Z] [16]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Clemastine and Doxepin. Depression [6A70-6A7Z] [16]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Clemastine and Maprotiline. Depression [6A70-6A7Z] [16]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Clemastine and Esketamine. Depression [6A70-6A7Z] [24]
Hyoscyamine DM804UR Moderate Additive anticholinergic effects by the combination of Clemastine and Hyoscyamine. Digestive system disease [DE2Z] [16]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Clemastine and Mepenzolate. Digestive system disease [DE2Z] [16]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Clemastine and Oxybutynine. Discovery agent [N.A.] [16]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Clemastine and Meclizine. Dizziness and giddiness [MB48] [16]
Trihexyphenidyl DMB19L8 Moderate Additive anticholinergic effects by the combination of Clemastine and Trihexyphenidyl. Dystonic disorder [8A02] [16]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Clemastine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [25]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Clemastine and Diphenhydramine. Episodic vestibular syndrome [AB31] [16]
Timolol DM3NXRU Moderate Decreased metabolism of Clemastine caused by Timolol mediated inhibition of CYP450 enzyme. Essential hypertension [BA00] [26]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Clemastine and Solifenacin. Functional bladder disorder [GC50] [16]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Clemastine and Tolterodine. Functional bladder disorder [GC50] [16]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Clemastine and Propantheline. Gastric ulcer [DA60] [16]
Isoflurophate DMBSK7X Moderate Antagonize the effect of Clemastine when combined with Isoflurophate. Glaucoma [9C61] [27]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Clemastine and Brimonidine. Glaucoma [9C61] [28]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Clemastine when combined with Pilocarpine. Glaucoma [9C61] [27]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Clemastine and Procarbazine. Hodgkin lymphoma [2B30] [20]
Potassium chloride DMMTAJC Major Increased risk of GI mucosal injury/bleeding risk by the combination of Clemastine and Potassium chloride. Hypo-kalaemia [5C77] [29]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Clemastine and Belladonna. Infectious gastroenteritis/colitis [1A40] [16]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Clemastine and Amantadine. Influenza [1E30-1E32] [30]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Clemastine and ITI-007. Insomnia [7A00-7A0Z] [16]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Clemastine and Clidinium. Irritable bowel syndrome [DD91] [16]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Clemastine and Dicyclomine. Irritable bowel syndrome [DD91] [16]
Physostigmine DM2N0TO Moderate Antagonize the effect of Clemastine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [19]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Clemastine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [31]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Clemastine and Lasmiditan. Migraine [8A80] [32]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Clemastine and Flibanserin. Mood disorder [6A60-6E23] [33]
Doxylamine DMKOXFE Moderate Additive anticholinergic effects by the combination of Clemastine and Doxylamine. Morning sickness disorder [SC00] [16]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Clemastine and Thalidomide. Multiple myeloma [2A83] [34]
Ozanimod DMT6AM2 Moderate Additive CNS depression effects by the combination of Clemastine and Ozanimod. Multiple sclerosis [8A40] [20]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Clemastine and Dimenhydrinate. Nausea/vomiting [MD90] [16]
Prochlorperazine DM53SRA Moderate Additive anticholinergic effects by the combination of Clemastine and Prochlorperazine. Nausea/vomiting [MD90] [16]
Promethazine DM6I5GR Moderate Additive anticholinergic effects by the combination of Clemastine and Promethazine. Nausea/vomiting [MD90] [16]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Clemastine and Cyclizine. Nausea/vomiting [MD90] [16]
Thiethylperazine DMU3IET Moderate Additive anticholinergic effects by the combination of Clemastine and Thiethylperazine. Nausea/vomiting [MD90] [16]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Clemastine and Apraclonidine. Optic nerve disorder [9C40] [28]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Clemastine and Dextropropoxyphene. Pain [MG30-MG3Z] [35]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Clemastine and Flavoxate. Pain [MG30-MG3Z] [16]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Clemastine and Biperiden. Parkinsonism [8A00] [16]
Procyclidine DMHFJDT Moderate Additive anticholinergic effects by the combination of Clemastine and Procyclidine. Parkinsonism [8A00] [16]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Clemastine and Orphenadrine. Parkinsonism [8A00] [16]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Clemastine and Methylscopolamine. Peptic ulcer [DA61] [16]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Clemastine and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Fluphenazine DMIT8LX Moderate Additive anticholinergic effects by the combination of Clemastine and Fluphenazine. Psychotic disorder [6A20-6A25] [16]
Triflupromazine DMKFQJP Moderate Additive anticholinergic effects by the combination of Clemastine and Triflupromazine. Psychotic disorder [6A20-6A25] [16]
Cyproheptadine DM92AH3 Moderate Additive anticholinergic effects by the combination of Clemastine and Cyproheptadine. Rheumatoid arthritis [FA20] [16]
Quetiapine DM1N62C Moderate Additive anticholinergic effects by the combination of Clemastine and Quetiapine. Schizophrenia [6A20] [16]
Mesoridazine DM2ZGAN Moderate Additive anticholinergic effects by the combination of Clemastine and Mesoridazine. Schizophrenia [6A20] [16]
Thioridazine DM35M8J Moderate Additive anticholinergic effects by the combination of Clemastine and Thioridazine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Clemastine and Aripiprazole. Schizophrenia [6A20] [16]
Iloperidone DM6AUFY Moderate Additive anticholinergic effects by the combination of Clemastine and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Additive anticholinergic effects by the combination of Clemastine and Paliperidone. Schizophrenia [6A20] [16]
Loxapine DM8AI9U Moderate Additive anticholinergic effects by the combination of Clemastine and Loxapine. Schizophrenia [6A20] [16]
Haloperidol DM96SE0 Moderate Additive anticholinergic effects by the combination of Clemastine and Haloperidol. Schizophrenia [6A20] [16]
Perphenazine DMA4MRX Moderate Additive anticholinergic effects by the combination of Clemastine and Perphenazine. Schizophrenia [6A20] [16]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Clemastine and Molindone. Schizophrenia [6A20] [16]
Chlorpromazine DMBGZI3 Moderate Additive anticholinergic effects by the combination of Clemastine and Chlorpromazine. Schizophrenia [6A20] [16]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Clemastine and Thiothixene. Schizophrenia [6A20] [16]
Clozapine DMFC71L Moderate Additive anticholinergic effects by the combination of Clemastine and Clozapine. Schizophrenia [6A20] [16]
Trifluoperazine DMKBYWI Moderate Additive anticholinergic effects by the combination of Clemastine and Trifluoperazine. Schizophrenia [6A20] [16]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Clemastine and Risperidone. Schizophrenia [6A20] [16]
Olanzapine DMPFN6Y Moderate Additive anticholinergic effects by the combination of Clemastine and Olanzapine. Schizophrenia [6A20] [16]
Asenapine DMSQZE2 Moderate Additive anticholinergic effects by the combination of Clemastine and Asenapine. Schizophrenia [6A20] [16]
Pimozide DMW83TP Moderate Additive anticholinergic effects by the combination of Clemastine and Pimozide. Schizophrenia [6A20] [16]
Atropine DMEN6X7 Moderate Additive anticholinergic effects by the combination of Clemastine and Atropine. Unspecific substance harmful effect [NE6Z] [16]
⏷ Show the Full List of 99 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clemastine 1.34 mg tablet 1.34 mg Oral Tablet Oral
Clemastine 1.34 mg tablet 1.34 mg 12 HR Extended Release Oral Tablet Oral
Clemastine 2.68 mg tablet 2.68 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6063).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073283.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91.
7 Stereoselective synthesis of (-)-hydroxyclemastine as a versatile intermediate for the H1 receptor antagonist clemastine. Arch Pharm Res. 2007 Dec;30(12):1521-5.
8 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
9 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
10 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
11 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
12 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
13 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
14 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
15 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
16 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
17 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
18 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
19 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
20 Canadian Pharmacists Association.
21 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
22 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
23 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
26 Edeki TI, He HB, Wood AJJ "Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction." JAMA 274 (1995): 1611-3. [PMID: 7474246]
27 Multum Information Services, Inc. Expert Review Panel.
28 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
29 Farquharson-Roberts MA, Giddings AE, Nunn AJ "Perforation of small bowel due to slow release potassium chloride (slow-K)." Br Med J 3 (1975): 206. [PMID: 1148734]
30 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
31 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
32 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
33 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
34 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
35 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]